See today's BioWorld
To read the full story, subscribe or sign in.

Opioid antagonism unlikely for Alkermes at adcom? Weight and see

Oct. 7, 2020
By Randy Osborne
As expected, weight mitigation and opioid-related risks turned up as the main concerns in briefing documents for the joint advisory panel meeting Oct. 9 to mull the approvability of Alkermes plc’s ALKS-3831.
BioWorld Drugs Regulatory Neurology/psychiatric FDA